What happens if the clinical trial treatment for Prostate Cancer doesn't work

What [facility removed]al Trial Treatment Doesn't Work

This is an important question that many prostate cancer patients face. Let me explain what typically happens and how your medical team approaches this situation.

Understanding Treatment Response

First, it's important to know that "not working" can mean different things:

Complete Response: Cancer shrinks significantly or disappears Partial Response: Cancer shrinks but doesn't disappear completely Stable Disease: Cancer stops growing (this is actually considered a benefit) Progressive Disease: Cancer continues to grow despite treatment

According to the CancerPatientLab webinars on prostate cancer treatment, when discussing bipolar androgen therapy (BAT), responses typically break down into thirds:

• One-third see marked improvement in PSA and cancer reduction
• One-third see PSA plateau (no progression = a benefit)
• One-third see PSA increase and cancer growth

What Happens Next: Your Treatment Options

1. Switching to a Different Treatment

If your current trial treatment isn't working, your oncologist will typically:

• Review your biomarkers and genetic testing - According to Andrew Armstrong's guidance on advanced prostate cancer, most men in community settings aren't getting adequate testing. You should ask your doctor about both germline (normal tissue) and tumor testing to identify which treatments might work for you. For example, finding a BRCA mutation indicates likely responsiveness to PARP inhibitors (drugs like olaparib).

• Consider combination approaches - The field has moved toward combining multiple drugs. For metastatic castrate-resistant prostate cancer, doctors may combine:

  • Androgen receptor inhibitors (like abiraterone or enzalutamide)
  • PARP inhibitors (for patients with DNA repair mutations)
  • Chemotherapy (like docetaxel or cabazitaxel)
  • Immunotherapy options

2. Exploring Other Clinical Trials

According to the CancerPatientLab resources, there are multiple trial options available:

• Trials testing new drug combinations
• Immunotherapy trials (checkpoint inhibitors, CAR-T cells, bispecific T-cell engagers)
• Trials for neuroendocrine prostate cancer (a more aggressive variant)
• Radiopharmaceutical trials (like lutetium-177 PSMA therapy)

3. Adaptive Therapy Approaches

An emerging strategy discussed by Dr. [removed] Gatenby involves "adaptive therapy" - rather than continuous treatment, your doctor may:

• Give you treatment until PSA drops to about 50% of pre-treatment value
• Stop treatment and let PSA rise back to baseline
• Restart treatment when it returns
• Adjust doses based on PSA response at each decision point

This approach aims to keep cancer cells sensitive to treatment longer while reducing side effects.

Important Monitoring Considerations

PSA Monitoring Can Be Tricky: According to Dr. [removed] McKay's guidance, PSA is a tricky marker to follow in castrate-resistant prostate cancer, especially with androgen receptor amplification. Your doctor may use additional monitoring methods:

• Imaging scans (CT, bone scans, PSMA PET)
• Liquid biopsies (blood tests measuring circulating tumor DNA)
• Fragmentomics (analyzing DNA fragmentation patterns)
• Physical symptoms and quality of life assessments

Bone Scan Flare: Be aware that sometimes bone scans can look worse before they look better - this doesn't necessarily mean the treatment is failing.

Questions to Ask Your Oncologist

If your trial treatment isn't working as expected, ask:

1. "What does my latest imaging and PSA results tell us about how the treatment is working?"
2. "Do I have any genetic mutations (like BRCA, mismatch repair deficiency) that would make me eligible for different treatments?"
3. "Are there other clinical trials I might be eligible for, and what would be the next best option?"
4. "Should we consider combination therapy with another drug?"
5. "How will we monitor whether a new treatment is working - what markers and scans will we use?"

The Reality of Advanced Prostate Cancer

According to Dr. [removed] Armstrong's research, there's an important reality to understand: most men in the U.S. don't receive many sequential therapies. There's often a steep drop-off where less than half of patients receive second-line therapy, and another half drop off before third-line treatment. This is partly because progression events can be very difficult on the body.

This is why hitting the cancer hard upfront with your best available treatment is so important - it can prolong survival and delay progression longer.

Moving Forward

The good news is that prostate cancer treatment has evolved significantly. As noted in the CancerPatientLab resources, there are now many more treatment options available than even a few years ago. The key is:

• Getting comprehensive genetic and biomarker testing
• Working with a genitourinary medical oncologist experienced in advanced prostate cancer
• Staying informed about clinical trial options
• Monitoring treatment response carefully with multiple markers (not just PSA)
• Planning ahead to preserve treatment options for future rounds

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: CancerPatientLab Webinars - "Guiding Personalized Treatment for Advanced Prostate Cancer (Round Two)" (Andrew Armstrong), "Bipolar Androgen Therapy for Prostate Cancer" (Emmanuel Antonarakis), "Multi-omic Analysis Guides the Decisions of Brian McCloskey" (Rana McKay, MD), and "Latest Insights from Applying Evolutionary Theory to the Treatment Strategies of Cancer Patients" (Bob Gatenby, MD)